Mental Health Clinics in Fort Lauderdale, FL Accepting Medicare
285 Mental Health Clinics found. Showing 201 - 220
 Preferred Educational & Psychological Services, Inc Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 610 Sw 34th St, Suite 301, Fort Lauderdale, FL 33315 Phone: 786-236-7795 |
Jada Wellness & Psychotherapy Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2900 E Oakland Park Blvd Fl 3, Fort Lauderdale, FL 33306 Phone: 440-346-1888 |
Nurmi Health Llc Psychologist Medicare: Not Enrolled in Medicare Practice Location: 101 Ne 3rd Ave # 1500, Fort Lauderdale, FL 33301 Phone: 954-247-8790 |
Claudia Rieman, Ph.d., Llc Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 1948 E Sunrise Blvd, Suite 8, Fort Lauderdale, FL 33304 Phone: 954-336-1105 |
New Beginnings Counseling Services, Pa Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 602 Sw 7th St, Fort Lauderdale, FL 33315 Phone: 954-798-5705 |
Ann Storck Center, Inc. Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 1790 Sw 43rd Way, Fort Lauderdale, FL 33317 Phone: 954-584-8000 Fax: 954-321-8863 |
Fort Lauderdale Psychiatrists Llc Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 915 Middle River Dr, Suite 317, Fort Lauderdale, FL 33304 Phone: 214-383-3200 Fax: 214-383-3211 |
Theracounsel,inc. Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 4546 N Federal Hwy, Fort Lauderdale, FL 33308 Phone: 954-564-9460 |
Private Mental Health Group, Llc Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 12 Se 7th St Ste 705, Fort Lauderdale, FL 33301 Phone: 954-794-9000 Fax: 754-800-2610 |
Neuropsych Wellness Llc Clinical Neuropsychologist Medicare: Not Enrolled in Medicare Practice Location: 110 E Broward Blvd Ste 1700, Fort Lauderdale, FL 33301 Phone: 917-626-6017 |
Be Fehr Counseling Llc Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2598 East Sunrise Blvd, Suite 2104, Fort Lauderdale, FL 33304 Phone: 754-304-9074 |
Professionals Trust Inc. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 2650 W State Road 84, L03, Fort Lauderdale, FL 33312 Phone: 954-327-0396 Fax: 954-327-0397 |
Evolutions Treatment Center Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 2901 W Cypress Creek Rd Ste 123, Fort Lauderdale, FL 33309 Phone: 954-915-7444 Fax: 954-206-0372 |
Ann Storck Center, Inc. Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 1790 Sw 43rd Way, Fort Lauderdale, FL 33317 Phone: 954-584-8000 Fax: 954-206-7699 |
Erica L. Hill, Ph.d., P.a. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1975 E Sunrise Blvd, Suite 534, Fort Lauderdale, FL 33304 Phone: 954-232-6882 Fax: 954-760-4358 |
Gina Joyreyes, Psy.d., Pllc Psychologist - Clinical Medicare: Not Enrolled in Medicare Practice Location: 915 Middle River Dr, Suite 320a, Fort Lauderdale, FL 33304 Phone: 954-243-8414 |
Broward Partnerships Social Worker - Clinical Medicare: Not Enrolled in Medicare Practice Location: 920 Nw 7th Ave, Fort Lauderdale, FL 33311 Phone: 954-779-3990 |
Clover Therapy Center Llc Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 2630 W Broward Blvd Ste 2031938, Fort Lauderdale, FL 33312 Phone: 786-860-2228 |
E Aksu, M.d., P.a. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 1219 Se 4th Ave, Fort Lauderdale, FL 33316 Phone: 954-462-7022 Fax: 954-763-3172 |
Wendi Cassand, Lcsw, Cap, Llc Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 4821 Ne 5th Ter, Suite A, Fort Lauderdale, FL 33334 Phone: 954-650-1706 Fax: 954-267-9567 |
News Archive
Researchers evaluate antibodies that inhibit SARS-CoV-2 RBD variants with a novel assay
A team of researchers recently discussed the potential role of a new assay in bridging a major gap in SARS-CoV-2 research. This assay can throw light on 1) the selection of complementary monoclonal antibody candidates and 2) rapid identification of the immune escape to emerging RBD variants following vaccination or natural infection.
Single submission of orphan drug designation annual report for both FDA and EMA
In recognition of World Rare Disease Day, the U.S. Food and Drug Administration and the European Medicines Agency (EMA) today announced a more streamlined process to help regulators better identify and share information throughout the development process of orphan drug and biologic products, which are developed specifically to treat rare medical conditions. Both agencies have agreed to accept the submission of a single annual report from sponsors of orphan drug and biologic products designated by both the United States and the European Union.
World Bank has approved a US$68 million credit to the Indian government for the Integrated Disease Surveillance project
India has made major gains in control of a number of communicable diseases and in improving overall health of its population. Nevertheless, with the increasing age profile of the population, India is in transition with the double burden of significant communicable diseases and increasing non-communicable diseases such as cardio-vascular diseases, cancers, diabetes and cataract blindness, maladies that usually affect higher income countries.
Promising method may help identify new antimicrobials to target CRE infection
In recent years, hospitals have reported dramatic increases in the number of cases of the highly contagious, difficult-to-treat, and often deadly antibiotic-resistant bacteria carbapenem-resistant Enterobacteriaceae (CRE). Now, investigators at Beth Israel Deaconess Medical Center have developed a promising method of identifying new antimicrobials that target these organisms. The research is published in April issue of the journal ASSAY and Drug Development Technologies.
Study: Alectinib 600 mg more effective than standard therapy in Asian ALK positive NSCLC patients
A subanalysis of the phase III ALEX study has shown that alectinib 600 mg twice daily is more effective than standard of care crizotinib in Asian patients with anaplastic lymphoma kinase (ALK) positive non-small-cell lung cancer (NSCLC), researchers report at the ESMO Asia 2017 Congress.
› Verified 2 days ago